LILLY FDA Approval NDA 020509

NDA 020509

LILLY

FDA Drug Application

Application #020509

Documents

Letter1998-08-25
Letter2002-05-01
Letter2004-05-26
Letter2005-04-28
Letter2006-04-07
Letter2014-06-12
Label2003-03-07
Label2004-05-19
Label2005-04-28
Label2010-03-26
Label2011-02-09
Label2015-10-13
Review2008-02-19
Letter2005-04-07
Letter2005-04-28
Letter2006-07-21
Letter2010-03-24
Letter2014-05-12
Label1998-08-25
Label2005-04-28
Label2013-05-08
Label2014-05-12
Review2007-11-19
Label2017-09-14
Letter2017-09-19
Pediatric Written Request1900-01-01
Label2018-06-21
Label2018-11-23
Letter2018-12-10
Review2019-02-15
Letter2019-05-15
Label2019-05-17
Pediatric Medical Review1900-01-01

Application Sponsors

NDA 020509LILLY

Marketing Status

Prescription001
Prescription002

Application Products

001INJECTABLE;INJECTIONEQ 200MG BASE/VIAL1GEMZARGEMCITABINE HYDROCHLORIDE
002INJECTABLE;INJECTIONEQ 1GM BASE/VIAL1GEMZARGEMCITABINE HYDROCHLORIDE

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP1996-05-15PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL2AP1997-04-11PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL3AP1997-10-10PRIORITY
LABELING; LabelingSUPPL4AP1997-09-18STANDARD
EFFICACY; EfficacySUPPL5AP1998-08-25STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL6AP1998-01-23PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL7AP1998-10-16PRIORITY
LABELING; LabelingSUPPL10AP2000-06-23STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL11AP1998-11-23PRIORITY
LABELING; LabelingSUPPL13AP2003-01-06STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL14AP2000-03-03PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL16AP2000-06-22PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL17AP2000-06-09PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL18AP2001-01-04PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL19AP2000-11-01PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL20AP2001-05-18PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL21AP2002-05-01PRIORITY
MANUF (CMC); Manufacturing (CMC)SUPPL22AP2002-11-13PRIORITY
EFFICACY; EfficacySUPPL29AP2004-05-19PRIORITY
LABELING; LabelingSUPPL32AP2005-04-20STANDARD
EFFICACY; EfficacySUPPL33AP2005-04-26PRIORITY
LABELING; LabelingSUPPL37AP2006-04-05STANDARD
EFFICACY; EfficacySUPPL39AP2006-07-14UNKNOWN
LABELING; LabelingSUPPL64AP2010-03-19STANDARD
LABELING; LabelingSUPPL69AP2011-02-04UNKNOWN
LABELING; LabelingSUPPL72AP2013-05-07STANDARD
LABELING; LabelingSUPPL75AP2014-06-10STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL76AP2014-08-11PRIORITY
LABELING; LabelingSUPPL77AP2014-05-08901 REQUIRED
LABELING; LabelingSUPPL79AP2017-09-13STANDARD
LABELING; LabelingSUPPL80AP2018-06-08STANDARD
LABELING; LabelingSUPPL81AP2018-11-20STANDARD
LABELING; LabelingSUPPL82AP2019-05-14STANDARD

Submissions Property Types

SUPPL1Null0
SUPPL2Null0
SUPPL3Null0
SUPPL6Null0
SUPPL7Null0
SUPPL11Null0
SUPPL14Null0
SUPPL16Null0
SUPPL17Null0
SUPPL18Null0
SUPPL19Null0
SUPPL20Null0
SUPPL21Null0
SUPPL22Null0
SUPPL33Null8
SUPPL64Null7
SUPPL69Null6
SUPPL72Null7
SUPPL75Null6
SUPPL76Null0
SUPPL77Null15
SUPPL79Null7
SUPPL80Null15
SUPPL81Null6
SUPPL82Null6

TE Codes

001PrescriptionAP
002PrescriptionAP

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 20509
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.